Toumai has many technical merits such as realistic 3D surgical field, fine manipulation of micro-instruments, and high dexterity in narrow space. This is integral to surgical operations in complex laparoscopies, including separation and hemostasis, suturing and knotting, and functional reconstruction. At the same time, it avoids large surgical trauma, bleeding, and high complication rate associated with traditional open surgery, and enables surgical operations that are truly precise, safe. It also could be applied to single-site surgery.

Before the world even imagined that 4 million drug-eluting stents would be available in 36 countries around the world, the founders of MicroPort® were imagining how they would impact the lives of people through technology. Their belief was that these medical technologies must be accessible to everyone. Relentless innovation has inspired promising product development and initiated strategic investments in emerging scientific platforms. Today, we see a promising path forward, one that addresses the most challenging healthcare issues, while allowing us to explore the ways to accelerate and broaden access to medical technology innovation.

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®, 02252.HK), a subsidiary of MicroPort Scientific Corporation (MicroPort®, 00853.HK), commenced its development for laparoscopic surgery robots in 2014 (as an internal incubation project of MicroPort® group), and established a company in China in 2015 when its began to develop Honghu orthopedic surgical robot. We are committed to meeting the peak demand for robotic surgery. By integrating the cutting-edge research and robot ontology, control algorithms, electrical engineering, image-based navigation and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the maturity and development of robotic surgery, and shape the era of super intelligent surgery.